TheMonz Posted - 1 day ago

$TARS Jefferies raised PT to $54 from $48.

NSAR Posted - 3 days ago

$TARS BO target? Has the making of one!!! Fast growth in unmet need, low market cap, tons of cash, recent rumor,

Biotechace Posted - 3 days ago

$TARS buy the dip

Quantumup Posted - 6 days ago

H.C. Wainwright⬆️PT $TARS $73 was $61/Buy, says "this launch has been remarkable:" c $334M (new) '25 sales (cons $293M); '25 Medicare coverage; a 50% sales force⬆️; direct2consumer campaign rollout/🔬driving expansion of in2 MGD w/ DB—on label already—+ing a substantial new segment:

making_money81 Posted - 6 days ago

$TARS would love to get back in this in the mid $30s

NJgolfer Posted - 6 days ago

$TARS hit my price target today

NSAR Posted - 6 days ago

$TARS rumor of BO?

DonCorleone77 Posted - 6 days ago

$TARS It's possible this might help explain why TARS couldn't hold its gain today. GS raised their PT but still only $41. Unfortunately, I do not have the full report: Tarsus Pharmaceuticals price target raised to $41 from $36 at Goldman Sachs Goldman Sachs raised the firm's price target on Tarsus Pharmaceuticals to $41 from $36 and keeps a Neutral rating on the shares. The company reported Q3 EPS topped estimates, posting a beat on Xdemvy net product sales at $48.1M, albeit with somewhat in-line number of vials dispensed, the analyst tells investors in a research note. Tarsus' commentary on the call focused on the improving outlook for Xdemvy in Q4 and beyond on the back of the recent sales force addition, the firm added.

DonCorleone77 Posted - 6 days ago

$TARS Tarsus Pharmaceuticals price target raised to $73 from $61 at H.C. Wainwright H.C. Wainwright raised the firm's price target on Tarsus Pharmaceuticals to $73 from $61 and keeps a Buy rating on the shares. The firm says Tarsus continues to beat estimates and that it continues to raise Xdemvy estimates on fundamental demand and unit-economics upside. In just over a year, H.C. Wainwright estimates Xdemvy is running at $250M annualized sales, the analyst tells investors in a research note.

DonCorleone77 Posted - 6 days ago

$TARS Attached is page 1 from the OpCo report referenced below.

DonCorleone77 Posted - 6 days ago

$TARS From Barclays today:

NSAR Posted - 6 days ago

$TARS I think a BO is near. Look at their revenue growth they’re flooded with cash. Their current product is crushing it, and they have three other drugs in the pipeline. Low market cap, and in an area of unmet needs.

DonCorleone77 Posted - 1 week ago

$TARS From Bank of America's Morning Meeting Notes. They have a 'Buy' rating and a $68 price target (up form $62):

Legeluga Posted - 1 week ago

$TARS I said if no bo I would fully close my position at market open, Im out here, glta longs.

IN0V8 Posted - 1 week ago

$TARS BofA Global Research raises PO to $68 from $62

briefingcom Posted - 1 week ago

Gapping up: $DLO +18.8% $ZETA +12.2% $DIS +9.7% $NN +8.4% $TARS +7.9%

DonCorleone77 Posted - 1 week ago

$TARS Momma asking for some new shoes!! Tarsus Pharmaceuticals price target raised to $65 from $63 at Oppenheimer Oppenheimer raised the firm's price target on Tarsus Pharmaceuticals to $65 from $63 and keeps an Outperform rating on the shares. The firm notes Tarsus reported Q3 with $48.1M topline, beating both its estimated $44.3M and Street's $43M estimate on strong 40% G/ N. Oppenheimer is impressed by the company's progress with target ECPs, with over 13,000 ECPs already prescribing Xdemvy. The firm expects Tarsus' initiatives to further drive Xdemvy's growth. Encouraged by positive MGD data, Oppenheimer looks forward to the company's strategic commercialization strategy.

Biotechace Posted - 1 week ago

$TARS Bank of America raises PT to $68 from $62

StockMvis Posted - 1 week ago

$TARS hmm short interest is still high and stock still undervalued. Guess we miss volume

WestEgg Posted - 1 week ago

$TARS a bit off with my revenue calculation- but looks like all the hedge funds that like a good buyout candidate are buying.

Capitulation_0 Posted - 1 week ago

$TARS what an odd AH action. not much volume after earnings. hmm

DonCorleone77 Posted - 1 week ago

$TARS Tarsus Pharmaceuticals reports Q3 EPS (61c), consensus (94c) Reports Q3 revenue $48.12M, consensus $43.44M. "The third quarter was our most successful to date for the launch of XDEMVY, with continued growth in patients served driven by broad physician adoption and strong payer coverage. We also brought forward groundbreaking new data that demonstrate the immense potential of XDEMVY across a range of patient types, continued to advance our robust pipeline, and further strengthened our executive team and Board with the addition of two world-class clinical leaders, Dr. Elizabeth Yeu and Dr. Kate Goodrich, respectively," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "With a sharp focus on execution, education, ease of access, and ongoing evidence generation, we expect to close the year with another strong quarter that we believe is just beginning to reflect the benefits of our expanded sales force and first ever direct-to-consumer TV campaign."

TheMonz Posted - 1 week ago

$TARS

ElmerFuddz Posted - 1 week ago

$TARS

ChessGM Posted - 1 week ago

$TARS Looked good on Nov 12th and looks even better now... https://stocktwits.com/ChessGM/message/592228144

ElmerFuddz Posted - 1 week ago

$TARS Wow!!!!

RonIsWrong Posted - 1 week ago

$TARS Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Generated $48.1 million in XDEMVY ® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across objective measures of Meibomian Gland Disease and important patient symptoms in Demodex blepharitis patients

RonIsWrong Posted - 1 week ago

$TARS Tarsus Pharmaceuticals Q3 2024 GAAP EPS $(0.61) Beats $(0.92) Estimate, Sales $48.12M Beat $43.44M Estimate Tarsus Pharmaceuticals (TARS) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.92) by 33.7 percent. The company reported quarterly sales of $48.12 million which beat the analyst consensus estimate of $43.44 million by 10.78 percent. This is a 2.47K percent increase over sales of $1.87 million the same period last year.

DonCorleone77 Posted - 1 week ago

$TARS From Barclays yesterday:

DonCorleone77 Posted - 1 week ago

$TARS Earnings after-hours today: Tarsus Pharmaceuticals appoints Goodrich to board of directors Tarsus Pharmaceuticals announced the appointment of Katherine Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors.